Breaks Categories: News

ThursdayJun 25, 2026 11:11 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reorganizes to Accelerate Global Commercialization Strategy

HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role. The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems,…

Continue Reading

ThursdayJun 25, 2026 9:50 am

NetworkNewsBreaks – American Fusion Inc. (OTC: AMFN) Finalizes Testing Protocol for 5MW Texatron(TM) Fusion Engine(TM)

American Fusion (OTC: AMFN) announced it has finalized the comprehensive testing protocol for its 5MW Pre-Production Texatron(TM) Fusion Engine(TM), establishing the engineering and scientific framework that will guide validation of the company's fusion energy platform. The protocol includes plasma density and temperature measurements, neutron monitoring, spectroscopy, electrical power analysis and calibration procedures, while also providing for independent scientific observation, public release of testing video and third-party evaluation of results as the company advances toward commercial validation. The company also announced continued expansion of its intellectual property portfolio with a new U.S. patent application covering aspects of the Texatron(TM) Fusion Engine(TM)…

Continue Reading

ThursdayJun 25, 2026 9:20 am

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it is featured in a BioMedWire editorial examining the growing market opportunity for next-generation DNA Damage Response ("DDR") inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," highlights the continued expansion of DDR-targeted therapies beyond PARP inhibitors as the global oncology, diagnostics and precision medicine markets continue to grow. The editorial highlights Onco-Innovations' lead candidate, ONC010™, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways. The…

Continue Reading

ThursdayJun 25, 2026 9:10 am

NetworkNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Completes Skaergaard Development Planning Workshop

Greenland Mines (NASDAQ: GRML) announced it has completed a three-day, multidisciplinary planning workshop for its Skaergaard Precious and Critical Metals Project in southeast Greenland, bringing together more than 15 international experts from GTK Mintec, the Geological Survey of Finland, SLR Consulting, WSP Denmark and other technical specialists. The June 22-24 sessions focused on advancing understanding of the orebody and processing pathways, planning 2026 drilling, sampling and environmental programs and establishing a roadmap toward an Initial Assessment ("IA") or Preliminary Economic Assessment ("PEA") and future development. The company said the workshop produced an integrated plan for the 2026 field campaign, a…

Continue Reading

WednesdayJun 24, 2026 1:12 pm

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development…

Continue Reading

WednesdayJun 24, 2026 10:50 am

NetworkNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Advances Jameson Land Basin Toward Exploration Drilling

Robert Price, CEO of Greenland Energy Company Energy, Oil & Gas Magazine profiles CEO Robert Price as company prepares for October 2026 exploration campaign in East Greenland Greenland Energy (NASDAQ: GLND) is advancing development of the Jameson Land Basin in East Greenland, an onshore petroleum basin that CEO Robert Price described as one of the world's last largely undrilled frontier oil regions. In an interview with Energy, Oil & Gas Magazine, Price said the company holds rights to up to a 70% interest in the basin and is leveraging extensive seismic data originally collected by Atlantic Richfield Company ("ARCO") during…

Continue Reading

WednesdayJun 24, 2026 10:25 am

NetworkNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development

Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its previously proposed acquisition of FST Development Company Limited. The company said that after reviewing its strategic priorities, capital allocation plans and recent development progress, it elected not to proceed with the transaction or the previously contemplated stock-based acquisition structure. Massimo said recent advancements in its internal development programs and strategic partnerships have strengthened its position in intelligent patrol systems, autonomous patrol vehicles, drone-assisted security technologies and AI-powered monitoring platforms, reducing the need for external acquisitions. To support these initiatives, the company’s controlling shareholder has committed up to $4 million in funding to accelerate…

Continue Reading

WednesdayJun 24, 2026 9:50 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety…

Continue Reading

WednesdayJun 24, 2026 9:40 am

NetworkNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning. Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company…

Continue Reading

WednesdayJun 24, 2026 9:30 am

NetworkNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Sells Gaming Assets in $1.76 Million Stock Transaction

Gaxos.ai (NASDAQ: GXAI) a developer of artificial intelligence applications across multiple industries, announced the completion of the sale of its gaming assets, including its portfolio of mobile games and Gaxos Gaming Labs, to privately held Game Foundry AI. The all-stock transaction was valued at approximately $1.76 million and is intended to support Gaxos’ strategy of focusing resources on its revenue-generating AI businesses and higher-margin commercial opportunities. Gaxos said the divestiture streamlines its operations by eliminating non-core assets and allows management to concentrate on business segments with stronger monetization potential. In a related transaction, the company acquired 250,000 shares of Game…

Continue Reading